Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesDermatologySummaCare Benign Lesion Coverage Policy | OpenPaye…
    Ask Trek AI about this page
    CurrentSummaCarePolicy N/A

    Benign Skin Lesion Removal Policy

    Customize your policy alerts

    Sign up for all summacare policy alerts

    Know when summacare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and medical necessity for removal or destruction of benign skin lesions for SummaCare commercial and Medicare members, including qualifying indications, cosmetic exclusions, documentation requirements, Medicare limitations, and applicable procedure codes.

    Policy Summary
    PayerSummaCare
    PolicyBenign Skin Lesion Removal Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOctober 8, 2026
    Last ReviewAug 6, 2026
    Next Review DateN/A
    Key ActionSubmit removal or destruction for authorization or coverage consideration with medical-record documentation showing that at least one applicable medical-necessity criterion is met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Lines of business covered
    10Commercial indication categories
    8Medicare lesion types addressed
    2Not-covered codes

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Cosmetic
    Default limitation

    Medical Necessity and Coverage Criteria

    Commercial Medical Necessity

    Commercial members: removal of benign skin lesions is medically necessary when ANY one of the following criteria is met.

    Commercial medical necessity

    • Symptomatic lesion

      • The lesion causes intense itching, burning, irritation, pain, or tenderness.
      • The lesion has chronic, recurrent, or persistent bleeding.
      • The lesion has physical evidence of inflammation or infection, including purulence, oozing, edema, or erythema.
      • The lesion has changed in physical appearance or enlarged.
      • The lesion obstructs an orifice.
      • The lesion clinically restricts eye function.
    • Diagnostic uncertainty: There is clinical uncertainty as to the likely diagnosis, particularly where malignancy is a realistic consideration based on lesion appearance, change in appearance, and/or nonresponse to conventional treatment.
    • Malignant transformation risk: The lesion is likely to turn malignant as documented by medical peer-reviewed literature.
    • Biopsy concern: A biopsy suggests the possibility of lesion malignancy or premalignancy.
    • Documented recurrent trauma: The lesion is in an anatomical region subjected to recurrent physical trauma, and the trauma has in fact occurred.
    • Additional wart circumstances

      • Wart removal qualifies under any of the general medical-necessity criteria above.
      • The wart is periocular and associated with chronic recurrent conjunctivitis thought to be secondary to lesion virus shedding.
      • The wart is spreading from one body area to another, particularly in an immunosuppressed patient, or is of recent origin in an immunocompromised patient.
      • The lesion is condyloma acuminata or molluscum contagiosum.

    Medicare Medical Necessity

    For the specified benign lesions, Medicare considers removal medically necessary and not cosmetic when ONE OR MORE of the following conditions is clearly documented in the medical record. The specified lesions are seborrheic keratoses, sebaceous or epidermoid cysts, skin tags, moles or nevi, acquired hyperkeratosis or keratoderma, molluscum contagiosum, milia, and viral warts. Destruction of actinic keratoses is covered without restrictions based on lesion or patient characteristics.

    Medicare medical necessity

    • Qualifying lesion symptoms or changes

      • The lesion is bleeding, intensely itchy, or painful.
      • The lesion has changed in physical appearance, including reddening or pigmentary change.
      • The lesion has recently enlarged or the number of lesions has increased.
      • The lesion has physical evidence of inflammation or infection, including purulence, oozing, edema, or erythema.

    Removal of benign asymptomatic or nonproblematic lesions is excluded when performed for cosmetic reasons, including appearance improvement, emotional distress, makeup trapping, or the lesion’s location alone. Sensitive anatomical location does not establish coverage when the lesion is not causing a clinical problem.

    CPT 0419T and 0420T are not covered for extensive neurofibroma destruction. CPT 0419T applies to destruction of more than 50 neurofibromas of the face, head, or neck; CPT 0420T applies to destruction of more than 100 neurofibromas of the trunk or extremities.

    When none of the policy’s qualifying medical indications is documented, SummaCare considers removal of a benign skin lesion cosmetic and not covered.

    Covered and Non-Covered Codes

    CPT Codes — Premalignant lesionsCPTCovered
    17000-17004Destruction, (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (eg, actinic keratoses)
    CPT Codes — Benign lesion removal and destructionCPTCovered
    11200-11201Removal of skin tags, multiple fibro cutaneous tags, any area
    11300-11313Shaving of epidermal or dermal lesions
    11400-11446Excision, benign lesions
    17110-17111Destruction, (e.g., laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular lesions
    54050-54065Destruction of lesion(s), penis (eg, condyloma, papilloma, molluscum contagiosum, herpetic vesicle)
    56501-56515Destruction of lesion(s), vulva
    57061 -7065Destruction of vaginal lesion(s)
    64788Excision of neurofibroma or neurolemmoma; cutaneous nerve
    64790Excision of neurofibroma or neurolemmoma; major peripheral nerve
    64792Excision of neurofibroma or neurolemmoma; extensive (including malignant type)
    1–10 of 11
    1/2
    CPT Codes NOT coveredCPTNot Covered
    0419TDestruction neurofibroma, extensive, (cutaneous, dermal extending into subcutaneous); face, head and neck, greater than 50 neurofibroma
    0420TDestruction neurofibroma, extensive, (cutaneous, dermal extending into subcutaneous); trunk and extremities, extensive, greater than 100 neurofibroma
    ModifierModifier
    25Modifier 25 for a significant, separately identifiable E&M service on the same day as a minor surgical procedure

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Documented Indication Required

    For both commercial and Medicare members, coverage consideration for benign lesion removal requires a documented qualifying medical indication in the medical record.

    • Document the indication supporting removal before requesting coverage or performing the service.
    • Qualifying indications may include symptoms, diagnostic uncertainty, malignancy or premalignancy concerns, documented recurrent trauma, or other policy-listed clinical circumstances.
    Documentation Required

    Document Medical Necessity

    Document medical necessity in sufficient clinical detail to establish that the lesion is problematic or otherwise meets a covered indication. Vague statements or location alone are insufficient.

    • Record qualifying symptoms such as intense itching, burning, irritation, pain, tenderness, or recurrent or persistent bleeding.

    Clinical Background

    A skin lesion is a nonspecific change in the skin and may be benign, malignant, or premalignant. Benign lesions include moles, sebaceous cysts, seborrheic keratoses, skin tags, callouses, corns, and warts; they may be pigmented, raised, flat, large, small, or fluid-filled. Removal techniques may include biopsy, shaving, scraping, excision, laser treatment, cautery, cryotherapy, or other methods. Coverage for removal depends on documented symptoms, functional impact, malignancy or premalignancy concern, recurrent trauma, or another qualifying policy indication rather than cosmetic preference alone.

    Policy Definitions

    Skin lesion
    DefinitionA nonspecific term referring to any change in the skin surface.
    Possible classificationA skin lesion may be benign, malignant, or premalignant.
    Physical characteristicsLesions may be pigmented, raised, flat, large, small, fluid-filled, or have other characteristics.
    Benign skin lesion
    DefinitionA non-cancerous growth that may become problematic because of changes in characteristics, size, location, or pressure on nearby blood vessels, nerves, or organs.
    Representative growthsMoles (nevi), sebaceous cysts, seborrheic keratoses, skin tags (acrochordon), callouses, corns, and warts.
    Policy Summary
    PayerSummaCare
    PolicyBenign Skin Lesion Removal Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOctober 8, 2026
    Last ReviewAug 6, 2026
    Next Review DateN/A
    Key ActionSubmit removal or destruction for authorization or coverage consideration with medical-record documentation showing that at least one applicable medical-necessity criterion is met.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCovered and Non-Covered CodesAuthorization, Documentation, and Denial RisksClinical BackgroundPolicy Definitions
  1. Eye or orifice involvement

    • The lesion obstructs an orifice.
    • The lesion clinically restricts eyelid function.
    • The lesion causes misdirection of the eyelashes or eye.
    • The lesion restricts the lacrimal puncta and interferes with tear flow.
    • The lesion touches the globe.
  2. Diagnostic uncertainty: There is clinical uncertainty as to the likely diagnosis, particularly where malignancy is a realistic consideration based on lesion appearance.
  3. Biopsy malignancy concern: A prior biopsy suggests or is indicative of lesion malignancy.
  4. Documented recurrent trauma: The lesion is in an anatomical region subject to recurrent physical trauma, and documentation confirms that the trauma has in fact occurred.
  5. Epidermal inclusion cyst risk

    • The epidermal inclusion or sebaceous cyst has recently enlarged.
    • There is a history of rupture or previous inflammation of the epidermal inclusion or sebaceous cyst.
    • The cyst is located where the patient is subject to risk of rupture.
  6. Additional wart circumstances

    • Wart removal qualifies under the general medical-necessity guidelines above.
    • The wart is periocular and associated with chronic recurrent conjunctivitis thought to be secondary to lesion virus shedding.
    • The wart is spreading from one body area to another, particularly in an immunosuppressed patient, or is of recent origin in an immunocompromised patient.
    • The lesion is condyloma acuminata or molluscum contagiosum.
    • Cervical dysplasia or pregnancy is associated with genital warts.
  7. Describe lesion changes, including change in appearance, reddening or pigmentary change, recent enlargement, or an increase in the number of lesions.
  8. Document physical evidence of inflammation or infection, including purulence, oozing, edema, or erythema.
  9. Include related findings when applicable, such as obstruction of an orifice, restriction of eye or eyelid function, diagnostic uncertainty, biopsy findings, recurrent physical trauma, rupture risk, prior rupture, or previous inflammation.
  10. For wart destruction, document the applicable qualifying circumstance, such as periocular disease with recurrent conjunctivitis, spread in an immunosuppressed or immunocompromised patient, condyloma acuminata, molluscum contagiosum, cervical dysplasia, or pregnancy associated with genital warts.
  11. Denial Risk

    Cosmetic Services: Notify Medicare Beneficiaries

    When a Medicare beneficiary requests removal of asymptomatic benign lesions for cosmetic purposes, Medicare will not cover the service and the beneficiary is liable for payment. Notify the beneficiary in advance and obtain signed acceptance of financial responsibility when possible.

    • Clearly state the charges and explain that Medicare will not cover cosmetic dermatological surgery.
    • Obtain the beneficiary's signature acknowledging responsibility for payment before performing the service.
    Billing Rule

    E&M Documentation and Modifier 25

    Medicare does not pay a separate E&M service on the same day as a minor surgical procedure unless a significant, separately identifiable medical service is rendered and fully documented. Use modifier 25 when the requirements are met.

    • Document the significant, separately identifiable service clearly in the medical record.
    • During the global period, a separate E&M service by the operating physician is payable only for a medical problem unrelated to the surgical procedure and must be fully documented.
    • Append modifier 25 to an eligible same-day E&M service.
    Denial Risk

    Cosmetic or Nonproblematic Lesion

    Removal of a cosmetic or nonproblematic lesion is not covered. Emotional distress, makeup trapping, and a lesion's location—including a sensitive anatomical location—do not establish medical necessity when the lesion is not causing a covered problem.

    • Do not submit removal as covered solely because the patient wants to improve appearance.
    • Sensitive or difficult anatomical location alone does not qualify the removal for coverage.
    Denial Risk

    No Qualifying Medical Indication

    Coverage may be denied when the documentation does not establish at least one qualifying medical indication under the policy. In the absence of a covered indication, SummaCare considers the service cosmetic.

    • Ensure the record connects the lesion and the requested procedure to a specific covered indication.
    • Do not rely on a nonspecific diagnosis, patient preference, or anatomic location alone.
    Billing Rule

    Unsupported Separate E&M Service

    A separate E&M service is unsupported when the record does not demonstrate a significant, separately identifiable service. Medicare may deny the E&M service when documentation is incomplete or when the service is not unrelated during the global period.

    • Same-day minor-procedure E&M services require complete documentation and modifier 25 when otherwise appropriate.
    • An operating physician's E&M service during the global period must address a medical problem unrelated to the procedure.
    Denial Risk

    Excluded Neurofibroma Destruction Codes

    The following extensive neurofibroma destruction procedures are listed as not covered under the policy.

    • 0419T — Destruction neurofibroma, extensive, cutaneous/dermal extending into subcutaneous; face, head and neck, greater than 50 neurofibromas.
    • 0420T — Destruction neurofibroma, extensive, cutaneous/dermal extending into subcutaneous; trunk and extremities, extensive, greater than 100 neurofibromas.
    Removal considerations
    Removal may be medically necessary when the lesion has become problematic; treatment may include biopsy, scraping, shaving, excision, laser, cautery, or liquid nitrogen.